In the last 20 years several clinical trials, designed to correct of hyperglycemia, have been consistently successful to prevent and to decrease microvascular complications of diabetes, while macrovascular complications have been only marginally affected by glucose control.įor many years, insulin, sulfonylureas and biguanides were the only available antidiabetic drugs and their failure to prevent CV diseases has been attributed to the difficulty to lower enough blood glucose concentration due to increased risk of hypoglycemia and increased body weight. Also diabetes remission is observed short time after bariatric surgery before clinical meaningful weight loss. This link is so strong that even a modest weight loss is often successful to improve hyperglycemia. Correction of hyperglycemia is therefore considered a priority of diabetes therapy and it has been pursued with drugs increasing insulin secretion and/or decreasing insulin resistance and obesity, a state of insulin resistance not only simply associated with diabetes but, more important, being a key factors linking T2DM and cardiovascular diseases (CV), the common clinical outcome of diabetes”. Both impaired beta-cell function and insulin resistance contribute to hyperglycemia, the diagnostic hallmark of diabetes. “The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing and represents a serious burden for patients and health care systems.
0 kommentar(er)
